Literature DB >> 2882775

Relationships between heart rate and PR interval during physiological and pharmacological interventions.

S G Carruthers, B McCall, B A Cordell, R Wu.   

Abstract

The relationships between heart rates (HR) and corresponding PR intervals (PR) were studied in 12 healthy young subjects during rest, standing and graduated treadmill exercise to heart rates of 160 to 170 beats min-1 and during the infusion of isoprenaline to heart rates of 100 to 110 beats min-1. During exercise, PR diminished with increasing HR. Over the range of HR from 60 to 160 beats min-1 all 12 individual subjects exhibited negative linear correlations between HR and PR described by the equation: PR (ms) = -0.351 HR (beats min-1) + 176.7 for composite data. During isoprenaline infusion the PR interval also diminished with increasing heart rate. Over the range of HR from 60 to 110 beats min-1, 11 of the 12 subjects exhibited negative linear correlations between HR and PR described by the equation: PR (ms) = -0.582 HR (beats min-1) + 186.5 for composite data. The exercise model was used to study the indirect (or rate-dependent) effects and the direct actions on atrioventricular conduction of beta-adrenoceptor blocking drugs and calcium channel antagonists, alone and in combination, in three groups of healthy subjects. Control and placebo observations on HR and PR at rest, standing and during exercise in these additional subjects also exhibited individual inverse linear relationships between HR and PR. Following the administration of beta-adrenoceptor blockers, PR were prolonged more than expected at the HR observed. Rate-adjusted PR prolongation during exercise exceeded standing which exceeded resting, indicating greater beta-adrenoceptor blockade in atrioventricular nodal tissue than in sinoatrial nodal tissue at each level of activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2882775      PMCID: PMC1386222          DOI: 10.1111/j.1365-2125.1987.tb03043.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  A COMPARISON OF ATRIO-VENTRICULAR CONDUCTION IN NORMAL CHILDREN AND IN PATIENTS WITH RHEUMATIC FEVER, GLOMERULONEPHRITIS, AND ACUTE FEBRILE ILLNESSES. A QUANTITATIVE STUDY WITH DETERMINATION OF THE P-R INDEX.

Authors:  M MIROWSKI; B J ROSENSTEIN; M MARKOWITZ
Journal:  Pediatrics       Date:  1964-03       Impact factor: 7.124

2.  P-R interval in relation to heart rate during exercise and the influence of posture and autonomic tone.

Authors:  J H Atterhög; E Loogna
Journal:  J Electrocardiol       Date:  1977       Impact factor: 1.438

3.  Atrioventricular conduction in acute rheumatic fever.

Authors:  M Clarke; J D Keith
Journal:  Br Heart J       Date:  1972-05

4.  "Normal" atrioventricular conduction times.

Authors:  W H Herbert; B J Sobol
Journal:  Am J Med       Date:  1970-02       Impact factor: 4.965

5.  Atrioventricular conduction in man. Effect of rate, exercise, isoproterenol and atropine on the P-R interval.

Authors:  J W Lister; E Stein; B D Kosowsky; S H Lau; A N Damato
Journal:  Am J Cardiol       Date:  1965-10       Impact factor: 2.778

6.  New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man.

Authors:  G Das; F N Talmers; A M Weissler
Journal:  Am J Cardiol       Date:  1975-09       Impact factor: 2.778

7.  Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding.

Authors:  O E Brodde; K Karad; H R Zerkowski; N Rohm; J C Reidemeister
Journal:  Circ Res       Date:  1983-12       Impact factor: 17.367

8.  Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding.

Authors:  G L Stiles; S Taylor; R J Lefkowitz
Journal:  Life Sci       Date:  1983-08-01       Impact factor: 5.037

  8 in total
  8 in total

1.  The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function.

Authors:  W R Danter; S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

2.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

3.  Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease.

Authors:  Takashi Kudo; Analyne Schroeder; Dawn H Loh; Dika Kuljis; Maria C Jordan; Kenneth P Roos; Christopher S Colwell
Journal:  Exp Neurol       Date:  2010-12-22       Impact factor: 5.330

4.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

5.  QRS Complex Detection and Measurement Algorithms for Multichannel ECGs in Cardiac Resynchronization Therapy Patients.

Authors:  Antonia E Curtin; Kevin V Burns; Alan J Bank; Theoden I Netoff
Journal:  IEEE J Transl Eng Health Med       Date:  2018-06-05       Impact factor: 3.316

6.  Prolongation of the PQ interval as a measure of therapeutic inequivalence between two formulations of diltiazem.

Authors:  O E Della Paschoa; V Luckow; D Trenk; E Jähnchen; S R Santos
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Sleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's disease.

Authors:  Dika Kuljis; Analyne M Schroeder; Takashi Kudo; Dawn H Loh; David L Willison; Christopher S Colwell
Journal:  Minerva Pneumol       Date:  2012-09

8.  Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.

Authors:  Elsayed Z Soliman; Jens D Lundgren; Mollie P Roediger; Daniel A Duprez; Zelalem Temesgen; Markus Bickel; Judith C Shlay; Charurut Somboonwit; Peter Reiss; James H Stein; James D Neaton
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.